ONCORUS INC(NASDAQ:ONCR) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ONCR. ONCR was compared to 562 industry peers in the Biotechnology industry. While ONCR seems to be doing ok healthwise, there are quite some concerns on its profitability. ONCR does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ONCR has reported negative net income.

ONCR had a negative operating cash flow in the past year.

ONCR had negative earnings in each of the past 5 years.

In the past 5 years ONCR always reported negative operating cash flow.

1.2 Ratios

ONCR has negative profitability rations, so we won't be analyzing them here.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONCR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, ONCR has more shares outstanding

ONCR has a worse debt/assets ratio than last year.

2.2 Solvency

ONCR has an Altman-Z score of -5.89. This is a bad value and indicates that ONCR is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -5.89, ONCR is doing worse than 68.01% of the companies in the same industry.

ONCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-5.89

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ONCR has a Current Ratio of 1.50. This is a normal value and indicates that ONCR is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 1.50, ONCR is doing worse than 81.67% of the companies in the same industry.

A Quick Ratio of 1.50 indicates that ONCR should not have too much problems paying its short term obligations.

ONCR has a Quick ratio of 1.50. This is amonst the worse of the industry: ONCR underperforms 80.55% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.5
Quick Ratio	1.5

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ONCR have decreased strongly by -28.78% in the last year.

EPS 1Y (TTM)-28.78%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-71.01%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 21.17% on average over the next years. This is a very strong growth

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y34.04%

EPS Next 2Y30.28%

EPS Next 3Y21.17%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ONCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONCR. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ONCR's earnings are expected to grow with 21.17% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y30.28%

EPS Next 3Y21.17%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ONCR!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ONCORUS INC

NASDAQ:ONCR (6/20/2023, 8:14:14 PM)

0.1206

-0.01 (-8.5%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-22 2023-05-22/amc

Earnings (Next)08-02 2023-08-02/bmo

Inst Owners9.11%

Inst Owner Change0%

Ins Owners11.14%

Ins Owner Change0%

Market Cap3.15M

Analysts45.71

Price Target5.1 (4128.86%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-34.88%

Min EPS beat(2)-65.27%

Max EPS beat(2)-4.49%

EPS beat(4)1

Avg EPS beat(4)-17.24%

Min EPS beat(4)-65.27%

Max EPS beat(4)1.09%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)53.85%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0.81%

EPS NY rev (1m)0%

EPS NY rev (3m)-21.5%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.1
P/tB	0.1
EV/EBITDA	N/A

EPS(TTM)-3.49

EYN/A

EPS(NY)-0.91

Fwd EYN/A

FCF(TTM)-2.83

FCFYN/A

OCF(TTM)-2.13

OCFYN/A

SpS0

BVpS1.19

TBVpS1.19

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	437.27%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.5
Quick Ratio	1.5
Altman-Z	-5.89

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)372.13%

Cap/Depr(5y)247.64%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-28.78%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-71.01%

EPS Next Y34.04%

EPS Next 2Y30.28%

EPS Next 3Y21.17%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-5.55%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-37.47%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-23.81%

OCF growth 3YN/A

OCF growth 5YN/A

ONCORUS INC (ONCR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens